The severe to very severe chronic obstructive pulmonary disease (COPD) drug market is becoming increasingly crowded as several LAMAs, LABA\/ICSs, LABA\/LAMAs, LABA\/LAMA\/ICSs, and, most recently, the PDE-3\/PDE-4 inhibitor Ohtuvayre and the IL-4\/IL-13 inhibitor Dupixent compete in the maintenance drug space. Unfortunately, none of these agents can reverse the progression of COPD or repair lung tissue; instead, current drug treatment focuses on improving breathing and reducing inflammation. Although inhaled medications can reduce the burden of COPD by easing its symptoms, patients\u2019 quality of life still suffers, and the disease remains one of the leading causes of death worldwide. Thus, significant unmet need remains for more-effective or disease-modifying therapies, especially for those patients with more-severe COPD whose symptoms are not adequately controlled with available therapies.<\/p>\n
Questions answered<\/strong><\/p>\n Product description<\/strong><\/p>\n Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/p>\n Geography:<\/strong> United States, France, Germany, United Kingdom<\/p>\n<\/div>\n Key analyses:<\/strong> Importance of clinical and nonclinical product attributes to physicians; Assessment of current drug performance against treatment drivers and goals;\u00a0Physician perceptions of unmet needs in the indication and related indications; Remaining drug development opportunities<\/p>\n<\/div>\n\n
\n